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A New Measure of HDL Function?*Alan T. Remaley, MD, PHDI n this issue of the Journal, Qi et al. (1) describe apotentially important advance in cardiovascularbiomarker testing related to high-density lipo-
protein cholesterol (HDL-C), the so called “good
cholesterol.” The story of how cholesterol is causally
related to cardiovascular disease (CVD) started more
than 100 years ago with the pioneering studies by
N. Anitschkow, who ﬁrst showed that feeding rabbits
a high-cholesterol diet induced atherosclerosis (2).
Later John Gofman, MD, PhD, in the 1950s, found by
analytical ultracentrifugation that cholesterol on
low-density lipoprotein (LDL) was a positive risk
factor for CVD, whereas cholesterol on HDL was
inversely related to CVD risk (3). This began the mod-
ern era of lipoprotein research and was the genesis
for measurement of the cholesterol content of HDL
(HDL-C) as the main metric for HDL. Subsequently,
diagnostic testing for HDL-C has become so ingrained
in medical practice that it is often incorrectly viewed
as being synonymous with HDL.SEE PAGE 355Recent improvements in technology related to HDL
proteomics and lipidomics have revealed its compo-
sitional complexity. Besides cholesterol, HDL is now
known to carry more than 100 different types of lipids
(4), many of which are potent bioactive signaling
molecules (4,5). Besides apolipoprotein A-I, its main
structural protein, approximately 80 different pro-
teins have been described to be associated with HDL*Editorials published in the Journal of the American College of Cardiology
reﬂect the views of the authors and do not necessarily represent the
views of JACC or the American College of Cardiology.
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grant from LipoScience Inc.(6). Perhaps not surprisingly, given its complexity,
HDL has been proposed to have numerous biological
functions (7). This has raised the important issue
about whether our current HDL-C test provides a full
assessment of HDL composition and function (8).
Compounding this concern are the results of several
recent clinical trials of different types of drugs for
raising HDL-C that have not shown so far the ex-
pected decrease in CVD events (9). Large genome-
wide association studies of common gene poly-
morphisms that modulate HDL-C levels have also
failed to show a clear association with CVD risk (10).
As a consequence, there is great interest in devel-
oping alternative measures of HDL both as diagnostic
tests for assessing CVD risk and as novel biomarkers
for drug development.
In the paper by Qi et al. (1), they investigate
whether the ratio of HDL-C to high-density lipopro-
tein particles (HDL-P) can be used as a predictor of
atherosclerosis progression. HDL-P refers to the par-
ticle count of HDL. In other words, it represents the
total number of HDL particles per volume of plasma
and is typically expressed as mmol/liter. The term
HDL-P was originally coined by Dr. Jim Otvos from
LipoScience (Raleigh North Carolina), who ﬁrst
developed a nuclear magnetic resonance (NMR)-
based method for quantifying lipoproteins (11). HDL-P
is now used as a more general term and can also be
determined by other analytical methods (12). The
NMR HDL-P test, which was used in this study, is
based on the detection of the proton signal from the
terminal methyl group of lipids on lipoproteins. This
signal can be used, not only to quantify the amount of
a lipoprotein present, but also its size, because
different-size lipoprotein particles have different
chemical shifts in their NMR spectra (11). A spectral
deconvolution algorithm based on the known NMR
spectrum of isolated lipoproteins of different sizes is
used to calculate the number of lipoprotein particles
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365present for each designated size class. In the case of
HDL, the NMR method can report 3 different size
classes (small, medium, and large), but these are
aggregated for calculating the total HDL-P count.
Similarly, one can also measure by NMR the other
major lipoprotein fractions, such as the low-density
lipoprotein particle (LDL-P) count. In fact, several
studies have shown LDL-P to be superior to the
cholesterol content of LDL (LDL-C) and apolipopro-
tein B as a positive risk marker for CVD (13). The NMR
LDL-P test was cleared by the U.S. Food and Drug
Administration (FDA) in 2008, and it is available
through LipoScience and other reference laboratories.
In 2012, the FDA cleared the Vantera clinical analyzer,
a 400-MHz NMR spectrometer produced by Lipo-
Science, for the high throughput measurement of
LDL-P, HDL-C, and triglycerides in routine hospital
laboratories. The NMR HDL-P test is not yet approved
by the FDA, but in several large studies (MESA [Multi-
Ethnic Study of Atherosclerosis] [14], JUPITER
[Justiﬁcation for the Use of Statins in Prevention: an
Intervention Trial Evaluating Rosuvastatin] [15], and
HPS [Heart Protection Study] [16]), it appeared to be
superior to HDL-C as a negative CVD risk marker.
The main hypothesis examined in this study by Qi
et al. (1) was whether HDL enriched in cholesterol
was less atheroprotective. This was determined by
calculating the ratio of HDL-C/HDL-P in 930 healthy
individuals from China. On the basis of this ratio,
HDL particles were estimated to contain on average
approximately 46 cholesterol molecules per particle,
but this differed by more than 3-fold in test subjects,
and the overall correlation between HDL-P and HDL-C
was relatively poor (r ¼ 0.378). Individuals in this
study were followed for 5 years, and atherosclerosis
progression was observed in approximately one-half
of the subjects, as determined by comparing results
from a baseline carotid ultrasound measurement to
one performed at the end of the study. Participants
were divided into 9 categories, depending on whether
they had low, medium, or high HDL-P and HDL-C.
Interestingly, HDL-C levels did not appear to be in-
versely related to the risk for atherosclerosis progres-
sion except for those in the lowest HDL-P subgroups.
By contrast, high HDL-P appeared to be inversely
related to atherosclerosis risk progression regardless
of the HDL-C level, but this association did not reach
statistical signiﬁcance except for those in the highest
HDL-C subgroups. Individualswith the highest HDL-C/
HDL-P ratios (>53) had a signiﬁcant 1.5-fold increase
risk for atherosclerosis progression compared with
individuals with the lowest HDL-C/HDL-P ratio (<41).
This relationship held even after adjustment for other
routine cardiovascular biomarkers, including LDL-P,and other risk factors, as well as after adjustment for
the use of lipid-lowering medications.
The reason for the association of atherosclerosis
progression with higher HDL-C/HDL-P ratios was not
assessed in this study, but several plausible mecha-
nisms were proposed. The most likely one is that
cholesterol enrichment of HDL decreases its ability to
promote the efﬂux of cholesterol from cells, which is
believed to be one of its main antiatherogenic func-
tions and has been shown to be inversely related to
CVD risk (17). It has also already been demonstrated
in vitro that adding exogenous cholesterol to HDL
limits its capacity to bind additional cholesterol
efﬂuxed from cells (18). It is also known that
phospholipid-rich, but cholesterol-poor, HDL sub-
fractions, such as pre-beta HDL, are especially good at
efﬂuxing cholesterol from cells, particularly by the
ABCA1 transporter (8,13,18). When HDL is enriched in
cholesterol, it may, in fact, turn into a net donor of
cholesterol to cells. This normally happens when HDL
delivers cholesterol to the liver for excretion or to the
adrenal gland for steroid hormone biosynthesis, but it
has been proposed that HDL, under certain patho-
logical conditions, may become dysfunctional and
can lead to the net deposition of cholesterol into
atherosclerotic plaque (19).
Although the results of this study are quite prom-
ising and could be readily implemented with existing
routine clinical laboratory assays, it is, of course,
important to replicate these results in larger studies
with longer observation periods. A more careful
assessment will also have to be made to show that
HDL-C/HDL-P ratio provides additional independent
predictive information over other currently used
cardiovascular biomarkers, particularly for those
subjects at intermediate CVD risk, a population on
which the test is most likely to be ﬁrst used. Finally, it
will eventually be important to demonstrate, not only
an association with atherosclerosis progression, but
that the HDL-C/HDL-P ratio is predictive of future
CVD based on clinical events, such as myocardial
infarction, revascularization, and stroke.
It has been a long and winding road in unraveling
the link between cholesterol and atherosclerosis, but
recent progress in understanding the complexity of
HDL coupled with new analytical procedures, such as
NMR-based lipoprotein testing, may lead to better
HDL-based biomarkers for drug development and
CVD risk assessment.
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